Inozyme Pharma
INZY
INZY was delisted on the 30th of June, 2025.
50 hedge funds and large institutions have $337M invested in Inozyme Pharma in 2021 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 20 increasing their positions, 13 reducing their positions, and 9 closing their positions.
54% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 13
2.56% more ownership
Funds ownership: 81.69% → 84.25% (+2.6%)
9% less funds holding
Funds holding: 55 → 50 (-5)
11% less capital invested
Capital invested by funds: $379M → $337M (-$42.3M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
56% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$4.56M |
| 2 |
DM
Deerfield Management
New York
|
+$3.74M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$3.46M |
| 4 |
O
OrbiMed
New York
|
+$3.28M |
| 5 |
BCM
Burrage Capital Management
Boston,
Massachusetts
|
+$1.27M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
CAAS Capital Management
New York
|
-$3.52M |
| 2 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$1.77M |
| 3 |
Millennium Management
New York
|
-$1.53M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$1.21M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$338K |
INZY Hedge Fund Activity: Q2 2021 in Review
50 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Inozyme Pharma (INZY) for Q2 2021, worth a combined $337M — down 11% from $379M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of INZY and 4 opened new positions — a net loss of 5 holders — while 13 trimmed existing stakes and 20 added.
The largest buyer was Wellington Management Group, adding an estimated $4.56M. The largest seller was CAAS Capital Management, exiting entirely with an estimated $3.52M sold.
- 50 institutional investors held Inozyme Pharma (INZY) as of Q2 2021, down from 55 in Q1 2021.
- Funds reported $337M of Inozyme Pharma stock for Q2 2021, down 11% quarter-over-quarter.
- 4 funds opened new Inozyme Pharma positions in Q2 2021 and 9 closed out, a net change of -5 holders.
- The largest Inozyme Pharma buyer in Q2 2021 was Wellington Management Group, an estimated $4.56M added.
- The largest Inozyme Pharma seller in Q2 2021 was CAAS Capital Management, an estimated $3.52M sold.
Based on aggregated 13F filings for Q2 2021.